Latest News
Cytokinetics, Incorporated
- Cytokinetics, Incorporated Estimates – XETR:KK3A
- Cytokinetics to present four aficamten studies at HFSA 2026
- Cytokinetics begins ASPEN-HCM study for MYQORZO in hypertrophic cardiomyopathy
- Cytokinetics To Announce Third Quarter Results On November 4, 2026
- Cytokinetics to Announce Third Quarter Results on November 4, 2026
- Form 144 CYTOKINETICS For: 21 October By Investing.com
- Cytokinetics EVP Fady Malik sells over $224,000 in stock By Investing.com
- Form 4 Cytokinetics Inc: Nancy Wysenski (Director) For: 16 October By Investing.com
- HC Wainwright maintains Buy rating on Cytokinetics with $140 target
- William Blair initiates Cytokinetics stock coverage with outperform rating
- Cytokinetics insiders, including CEO, sell sign...
- Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Headlines from the last 30 days, linking to the original publishers. See all market news →